相似文献
1
In vitro activity of josamycin against aerobic gram-positive cocci and anaerobes.
Antimicrob Agents Chemother. 1976 Jun;9(6):988-93. doi: 10.1128/AAC.9.6.988.
2
Josamycin and rosamicin: in vitro comparisons with erythromycin and clindamycin.
Antimicrob Agents Chemother. 1976 Oct;10(4):773-5. doi: 10.1128/AAC.10.4.773.
3
In vitro susceptibility of common clinical anaerobic and aerobic isolates against josamycin.
Antimicrob Agents Chemother. 1976 Aug;10(2):253-7. doi: 10.1128/AAC.10.2.253.
4
In vitro activity of josamycin and rosamicin against Bacteroides fragilis compared with clindamycin, erythromycin, and metronidazole.
Antimicrob Agents Chemother. 1976 Jul;10(1):188-90. doi: 10.1128/AAC.10.1.188.
5
Comparative in vitro activity of A-56268.
Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):798-802. doi: 10.1007/BF01975054.
6
Josamycin: interpretation of inhibition zones with the Bauer-Kirby agar disk diffusion test as compared with erythromycin.
Chemotherapy. 1986;32(4):336-43. doi: 10.1159/000238432.
7
Coumermycin: in vitro activity against 251 clinical isolates of bacteria compared with the activities of eight other antibacterial agents.
Acta Pathol Microbiol Immunol Scand B. 1986 Apr;94(2):85-8. doi: 10.1111/j.1699-0463.1986.tb03024.x.
8
The in-vitro activity of roxithromycin, a new macrolide antibiotic, in comparison with that of erythromycin.
Drugs Exp Clin Res. 1987;13(9):563-6.
9
In vitro activity and clinical efficacy of clindamycin in the treatment of infections due to anaerobic bacteria.
J Infect Dis. 1977 Mar;135 Suppl:S49-53. doi: 10.1093/infdis/135.supplement.s49.
10
In vitro susceptibility studies with josamycin and erythromycin.
Antimicrob Agents Chemother. 1976 Mar;9(3):546-8. doi: 10.1128/AAC.9.3.546.
引用本文的文献
1
Josamycin-induced pedal oedema.
BMJ. 1993 Jul 3;307(6895):26. doi: 10.1136/bmj.307.6895.26-a.
2
In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.
Antimicrob Agents Chemother. 1984 Apr;25(4):529-31. doi: 10.1128/AAC.25.4.529.
3
In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.
Antimicrob Agents Chemother. 1983 Aug;24(2):209-15. doi: 10.1128/AAC.24.2.209.
4
Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965).
J Clin Microbiol. 1986 Aug;24(2):233-9. doi: 10.1128/jcm.24.2.233-239.1986.
5
Synergy between RU 28965 (roxithromycin) and human neutrophils for bactericidal activity in vitro.
Antimicrob Agents Chemother. 1986 Jul;30(1):137-42. doi: 10.1128/AAC.30.1.137.
6
In vivo effects of josamycin, erythromycin, and placebo therapy on nasal carriage of Staphylococcus aureus.
Antimicrob Agents Chemother. 1977 Mar;11(3):407-10. doi: 10.1128/AAC.11.3.407.
7
In vitro activity of rosamicin, josamycin, erythromycin, and clindamycin against beta-lactamase-nagative and beta-lactamase-positive strains of Neisseria gonorrhoeae.
Antimicrob Agents Chemother. 1979 Feb;15(2):243-5. doi: 10.1128/AAC.15.2.243.
本文引用的文献
1
The antibacterial action of erythromycin.
Proc Soc Exp Biol Med. 1952 Oct;81(1):175-83. doi: 10.3181/00379727-81-19815.
2
Standardized antimicrobial disc susceptibility testing of anaerobic bacteria. I. Susceptibility of Bacteroides fragilis to tetracycline.
Appl Microbiol. 1972 Feb;23(2):268-75. doi: 10.1128/am.23.2.268-275.1972.
3
Influence of food and hepatobiliary disease on the excretion of josamycin.
Pharmacology. 1972;8(4):336-43. doi: 10.1159/000136351.
Zotero 插件